StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences total product sales excluding Veklury (Base business, $M) ($M)

Form 8-K Total Revenue Summary

QuarterlyAnnual
Latest, Q2 2026
7,604
Period ended Jun 30, 2026
Change on a year earlier
+9.7%
6,934 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal product sales excluding Veklury (Base business, $M) ($M)Year on yearSource
Q2 2026Jun 30, 20267,604+9.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20266,802+7.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 20257,691+6.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 20257,068+3.6%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20256,934+3.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20256,311+3.6%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 20247,198+13.4%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 20246,823+7.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20246,698+6.2%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 20246,092+6.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 20236,350+0.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 20236,358+5.0%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 20236,308+10.8%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 20235,733+14.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 20226,333+9.1%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 20226,053+11.4%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Breakdown

What makes up total product sales excluding veklury (base business, $m)

Cite this data

StockData. (2026). Gilead Sciences Total product sales excluding Veklury (Base business, $M) ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rev_product_ex_veklury

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.